Cargando…

Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19

Patients with cancer have many comorbidities that increase their risk of death from Coronavirus disease 2019 (COVID-19). Anti-spike monoclonal antibodies (mAbs) reduce the risk of hospitalization or death from COVID-19 in the general population. To our knowledge, no studies have focused on the clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Arvanitis, Panos, Lerner, Alexis Hope, Vieira, Kendra, Almaghlouth, Nouf, Farmakiotis, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923655/
https://www.ncbi.nlm.nih.gov/pubmed/36780118
http://dx.doi.org/10.1007/s10238-023-01019-y
_version_ 1784887762030166016
author Arvanitis, Panos
Lerner, Alexis Hope
Vieira, Kendra
Almaghlouth, Nouf
Farmakiotis, Dimitrios
author_facet Arvanitis, Panos
Lerner, Alexis Hope
Vieira, Kendra
Almaghlouth, Nouf
Farmakiotis, Dimitrios
author_sort Arvanitis, Panos
collection PubMed
description Patients with cancer have many comorbidities that increase their risk of death from Coronavirus disease 2019 (COVID-19). Anti-spike monoclonal antibodies (mAbs) reduce the risk of hospitalization or death from COVID-19 in the general population. To our knowledge, no studies have focused on the clinical efficacy of mAbs compared to no outpatient treatment exclusively among patients with solid tumors and hematologic malignancies, who are often excluded from clinical trials. We studied patients with cancer who had COVID-19 between 11.9.2020 and 7.21.2022 and received mAbs in an outpatient setting. We compared hospitalization and mortality rates to those of patients with cancer concurrently diagnosed with COVID-19, who were eligible for mAbs, but did not receive any outpatient treatment. 63 patients received mAbs and 89 no outpatient treatment. Administration of mAbs was associated with lower 90-day hospitalization (20.6% vs. 60.7%, p <0.001), all-cause (6.3% vs. 19.1%, p 0.025) and COVID-19-attributed (3.2% vs. 14.6%, p 0.019) mortality rates, and lower peak O(2) requirements (ordinal Odds Ratio [OR] = 0.33, 95% Confidence Intervals [CI] = 0.20–0.53). Administration of mAbs (aHR 0.21, p <0.001), age (≥ 60 years, adjusted Hazard Ratio [aHR] 1.86, p=0.033), and metastases (aHR 0.41, p 0.007) were independently associated with hospitalization. mAb treatment remained significantly associated with all-cause (aHR 0.27, p 0.019) and COVID-19-attributed (aHR 0.19, p 0.031) mortality, after adjustment for other factors. mAb administration was associated with improved clinical outcomes among vulnerable patients with cancer and COVID-19. With no mAbs approved currently for treatment against the prevalent circulating variants, the development of new mAbs should be a research priority.
format Online
Article
Text
id pubmed-9923655
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-99236552023-02-13 Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19 Arvanitis, Panos Lerner, Alexis Hope Vieira, Kendra Almaghlouth, Nouf Farmakiotis, Dimitrios Clin Exp Med Research Patients with cancer have many comorbidities that increase their risk of death from Coronavirus disease 2019 (COVID-19). Anti-spike monoclonal antibodies (mAbs) reduce the risk of hospitalization or death from COVID-19 in the general population. To our knowledge, no studies have focused on the clinical efficacy of mAbs compared to no outpatient treatment exclusively among patients with solid tumors and hematologic malignancies, who are often excluded from clinical trials. We studied patients with cancer who had COVID-19 between 11.9.2020 and 7.21.2022 and received mAbs in an outpatient setting. We compared hospitalization and mortality rates to those of patients with cancer concurrently diagnosed with COVID-19, who were eligible for mAbs, but did not receive any outpatient treatment. 63 patients received mAbs and 89 no outpatient treatment. Administration of mAbs was associated with lower 90-day hospitalization (20.6% vs. 60.7%, p <0.001), all-cause (6.3% vs. 19.1%, p 0.025) and COVID-19-attributed (3.2% vs. 14.6%, p 0.019) mortality rates, and lower peak O(2) requirements (ordinal Odds Ratio [OR] = 0.33, 95% Confidence Intervals [CI] = 0.20–0.53). Administration of mAbs (aHR 0.21, p <0.001), age (≥ 60 years, adjusted Hazard Ratio [aHR] 1.86, p=0.033), and metastases (aHR 0.41, p 0.007) were independently associated with hospitalization. mAb treatment remained significantly associated with all-cause (aHR 0.27, p 0.019) and COVID-19-attributed (aHR 0.19, p 0.031) mortality, after adjustment for other factors. mAb administration was associated with improved clinical outcomes among vulnerable patients with cancer and COVID-19. With no mAbs approved currently for treatment against the prevalent circulating variants, the development of new mAbs should be a research priority. Springer International Publishing 2023-02-13 /pmc/articles/PMC9923655/ /pubmed/36780118 http://dx.doi.org/10.1007/s10238-023-01019-y Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Research
Arvanitis, Panos
Lerner, Alexis Hope
Vieira, Kendra
Almaghlouth, Nouf
Farmakiotis, Dimitrios
Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19
title Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19
title_full Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19
title_fullStr Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19
title_full_unstemmed Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19
title_short Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19
title_sort outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and covid-19
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923655/
https://www.ncbi.nlm.nih.gov/pubmed/36780118
http://dx.doi.org/10.1007/s10238-023-01019-y
work_keys_str_mv AT arvanitispanos outpatientantispikemonoclonalantibodyadministrationisassociatedwithdecreasedmorbidityandmortalityamongpatientswithcancerandcovid19
AT lerneralexishope outpatientantispikemonoclonalantibodyadministrationisassociatedwithdecreasedmorbidityandmortalityamongpatientswithcancerandcovid19
AT vieirakendra outpatientantispikemonoclonalantibodyadministrationisassociatedwithdecreasedmorbidityandmortalityamongpatientswithcancerandcovid19
AT almaghlouthnouf outpatientantispikemonoclonalantibodyadministrationisassociatedwithdecreasedmorbidityandmortalityamongpatientswithcancerandcovid19
AT farmakiotisdimitrios outpatientantispikemonoclonalantibodyadministrationisassociatedwithdecreasedmorbidityandmortalityamongpatientswithcancerandcovid19